Moderna (NASDAQ: MRNA) Sees Analyst Confidence and Pipeline Expansion

• Piper Sandler reiterated an Overweight rating for Moderna and raised its price target to $77.00.
• Moderna's seasonal flu vaccine, mFlusiva, received a unanimous 9-0 endorsement from an FDA advisory panel.
• The company is expanding its research pipeline into new cancer treatments and autoimmune diseases.

Moderna (NASDAQ: MRNA) is a biotechnology company that focuses on messenger RNA (mRNA) science. The company gained global recognition for developing one of the primary COVID-19 vaccines. It continues to research and develop new vaccines and treatments using its mRNA platform, competing in the pharmaceutical and biotech space.

On June 26, 2026, investment firm Piper Sandler confirmed its positive view on Moderna by reiterating its Overweight rating. An Overweight rating suggests an analyst believes the stock will perform better than others in its sector. The firm also raised its price target, an estimate of the stock's future value, to $77.00 from $69.00.

This analyst confidence follows key company developments. Moderna recently received a unanimous 9-0 endorsement from an FDA advisory panel for its seasonal flu vaccine, mFlusiva, as highlighted by Zacks. This favorable vote for adults aged 50 and older significantly increases the chances of the vaccine receiving final FDA approval.

At its Science Day event, Moderna also showcased its expanding research pipeline. The company is advancing new cancer treatments, including mRNA-2808 for multiple myeloma and mRNA-2151 for ovarian cancer. It also introduced mRNA-6007, a new modality for autoimmune diseases, demonstrating its strategy to diversify beyond infectious disease vaccines.

CEO Stéphane Bancel stated the company is executing a plan to manage three commercial franchises while investing in research. Reflecting this positive news, Moderna's stock is priced at $66.23, a gain of 10.84% for the day, with a 52-week high of $67.74 and a market capitalization of approximately $26.28 billion.